Information Provided By: 
Fly News Breaks for June 30, 2015
INSY
Jun 30, 2015 | 08:52 EDT
Piper Jaffray raised its price target on Insys Therapeutics to $46 from $38, citing the optionality available to the company from its pipeline, which the firm said it views as the most attractive pipeline among small- and mid-cap names in specialty pharma. The firm estimates that Insys shares are "barely ascribing meaningful value" to the company’s pipeline at current levels and that its Subsys drug may have greater peak sales potential than previously recognized.
News For INSY From the Last 2 Days
There are no results for your query INSY
